Leiden, the Netherlands, December 11, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective...
Lynk Pharmaceuticals Co., Ltd. (referred to as "Lynk Pharmaceuticals"), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of ankylosing spondylitis (AS).
--Aileron Therapeutics, Inc., a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced positive topline data from Cohort 2
HANGZHOU, China,Aug. 9, 2023/PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced positive topline data from a Phase II clinical tria...
Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The ...
Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2
The article reports that Alpharetta, Georgia-based Clearside Biomedical has completed patient enrollment for the phase II clinical trial of its triamcinolone acetonide for the treatment of macular edema associated with non-infectious uveitis.EBSCO_AspOphthalmology Times...
“Cebranopadol is so exciting because preliminary data suggest that it can treat pain as effectively as opioids but has much lower potential for abuse, produces significantly less respiratory depression and leads to n...
the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vacc...
the timing and availability of data for the VAX-24 infant Phase 2 study; the timing and availability of data for the VAX-31 adult Phase 3 studies and infant Phase 2 study; the demand for Vaxcyte’s v...